Fewer missed cancers. Fewer unnecessary biopsies.
Lung cancer screening has two problems: finding eligible patients (20 pack-year history) and diagnosing nodules accurately. Is this cancer?
We built AI for both:
3 Baseline
15.6 (4.1) mm, 1457 (31) mm³
Malignancy Risk: 55%
*LungAI performance data from internal retrospective validation on NLST held-out data. LungAI is an investigational clinical decision support tool and does not replace physician judgment.
The numbers that make early detection urgent
Americans die from lung cancer every year, more than breast, colon, and prostate combined
Of eligible Americans are currently screened for lung cancer each year
Of lung cancers are still diagnosed at late stage, when 5-year survival is under 9%
5-year survival rate when lung cancer is caught early at Stage I or II
Americans are eligible for free annual LDCT screening
Screened in underserved FQHC communities, where the gap is widest
Sources: ACS Cancer Facts 2024, USPSTF 2021, NLST, NCI SEER
One platform. Three partners.
Every patient found.
Lung cancer screening fails because the system is fragmented. FQHCs have the patients. Hospitals have the scanners. Payers have the incentive. We connect all three.
FQHCs serve 34M+ lives, many with the highest smoking prevalence and lowest screening rates. LungIQ scans EHR data to identify eligible patients, even when smoking history was never entered into structured fields.
- LungIQ 0.97 AUROC patient identification
- 9x faster than manual chart review
- Eligible patients referred to partner imaging centers
- Reimbursable shared decision-making visits (G0296)
Hospitals receive a steady referral pipeline from FQHC partners. Post-FDA clearance, LungAI adds a reimbursable AI diagnostic layer inside the radiologist's existing viewer. No new workstation. No new login.
- LungIQ Identify eligible patients in-system too
- LungAI Malignancy scoring 0 to 100, per nodule
- New revenue via CPT 0721T (post-FDA clearance)
- Fewer missed cancers. Fewer unnecessary biopsies.
*Pre-FDA 510(k) clearance. NLST held-out retrospective study. Results may differ in prospective clinical use.
LDCT screening is already an ACA-mandated benefit. Payers are paying for it. The question is what they're getting from it. Earlier detection shifts costs from $200K+ per patient (Stage IV) to $54K (Stage I).
- No new coverage policy or billing model required
- 4 to 6x ROI from early detection vs late-stage treatment
- HEDIS lung screening measure expected (NCQA)
- Claims-validated PMPM model, built with your actuaries
Ready to close the lung cancer screening gap in your community?
Whether you're an FQHC, health system, or health plan, we have a program built for you.
Partner with us